W J van Venrooij
Overview
Explore the profile of W J van Venrooij including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
234
Citations
6202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Venrooij W, van Loon-Klaassen L
Mol Biol Rep
. 2013 Nov;
1(3):167-71.
PMID: 24197513
(1) When the intracellular amino acid pool is prelabelled and subsequently chased in non-radioactive medium, the radioactivity of the amino acid pool is not found to have been incorporated into...
2.
van Engelen B, van Venrooij W
J Clin Neuromuscul Dis
. 2008 Dec;
2(1):1-2.
PMID: 19078593
No abstract available.
3.
van Venrooij W
Ned Tijdschr Geneeskd
. 2008 Jun;
152(21):1243-4.
PMID: 18578455
No abstract available.
4.
Vannini A, Cheung K, Fusconi M, Stammen-Vogelzangs J, Drenth J, DallAglio A, et al.
Ann Rheum Dis
. 2006 Sep;
66(4):511-6.
PMID: 16984940
Background: Antibodies directed against citrullinated proteins (eg anti-cyclic citrullinated peptide (CCP)) have excellent diagnostic and good prognostic potential for rheumatoid arthritis. Type 1 autoimmune hepatitis (AIH-1) is a chronic liver...
5.
Hengstman G, ter Laak H, Vree Egberts W, Lundberg I, Moutsopoulos H, Vencovsky J, et al.
Ann Rheum Dis
. 2006 May;
65(12):1635-8.
PMID: 16679430
Objective: To elucidate the clinical importance of the anti-signal recognition particle (SRP) autoantibody in patients with myositis. Methods: Retrospective systematic assessment of the clinical, laboratory and histological characteristics of 23...
6.
Bronner I, van der Meulen M, de Visser M, Kalmijn S, van Venrooij W, Voskuyl A, et al.
Ann Rheum Dis
. 2006 Apr;
65(11):1456-61.
PMID: 16606652
Background: Although polymyositis and dermatomyositis are regarded as treatable disorders, prognosis is not well known, as in the literature long-term outcome and prognostic factors vary widely. Aim: To analyse the...
7.
Hengstman G, Vree Egberts W, Seelig H, Lundberg I, Moutsopoulos H, Doria A, et al.
Ann Rheum Dis
. 2006 Jan;
65(2):242-5.
PMID: 16410528
Objectives: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis. Methods: A systematic assessment of the clinical, laboratory, and...
8.
Zendman A, van Venrooij W, Pruijn G
Rheumatology (Oxford)
. 2005 Sep;
45(1):20-5.
PMID: 16188946
No abstract available.
9.
Hengstman G, van Brenk L, Vree Egberts W, van der Kooi E, Borm G, Padberg G, et al.
J Neurol
. 2005 Feb;
252(5):534-7.
PMID: 15726253
Myositis specific autoantibodies (MSAs) are proven to be specific for myositis compared with other inflammatory connective tissue diseases. Their specificity compared, however, with other neuromuscular disorders, which are included in...
10.
van Gaalen F, Linn-Rasker S, van Venrooij W, de Jong B, Breedveld F, Verweij C, et al.
Arthritis Rheum
. 2004 Mar;
50(3):709-15.
PMID: 15022309
Objective: Rheumatoid arthritis (RA) is a common, severe, chronic inflammatory joint disease. Since the disease may initially be indistinguishable from other forms of arthritis, early diagnosis can be difficult. Autoantibodies...